重度银屑病患者晚期肝纤维化患病率研究
该前瞻性观察队列研究纳入400例重度银屑病患者,其中333例成功完成瞬时弹性成像检查。结果显示14.1%(95%CI 10.4%-17.9%)的患者存在晚期肝纤维化,中心性肥胖(腰围)、胰岛素抵抗、天冬氨酸氨基转移酶水平、血小板计数、银屑病疾病严重程度及减少酒精使用是晚期纤维化的相关临床因素。
要点
- 重度银屑病患者中晚期肝纤维化患病率为14.1%(95%CI 10.4%-17.9%)。
- 中心性肥胖(腰围)和胰岛素抵抗与晚期肝纤维化相关。
- 临床应关注重度银屑病患者的肝纤维化筛查。
核心结论
- 重度银屑病患者中晚期肝纤维化较为常见。
- 腹部肥胖(腰围)和胰岛素抵抗与晚期肝纤维化的存在相关。
研究设计与样本
- 研究为前瞻性观察队列研究(Co-morbidities in Severe Psoriasis study),于2012年10月18日至2015年4月2日在伦敦及英格兰东南部一家大型中心开展。
- 共招募400例重度银屑病成人患者(银屑病面积严重指数评分≥10),来自门诊。
- 最终分析纳入333例成功完成瞬时弹性成像扫描的患者,其中女性108例、男性289例,平均(SD)年龄49.5(13)岁。
主要发现
- 晚期纤维化的最佳拟合模型包含的临床因素为:中心性肥胖(腰围)、胰岛素抵抗、天冬氨酸氨基转移酶水平、血小板计数、银屑病疾病严重程度及减少酒精使用(R2 = 0.54)。
关键数值与推荐
- 晚期肝纤维化通过瞬时弹性成像(非侵入性标准检测)诊断。
- 重度银屑病定义为银屑病面积严重指数评分≥10。
临床怎么用
- 对重度银屑病患者,可考虑评估中心性肥胖(腰围)和胰岛素抵抗以识别晚期肝纤维化高风险者。
- 需进一步纵向研究描述中心性肥胖、胰岛素抵抗和炎症的肝脏后遗症,以及系统性药物(甲氨蝶呤和生物制剂)的影响,以指导个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Advanced liver fibrosis is a precursor to cirrhosis, a leading cause of mortality. People with severe psoriasis are at risk for liver disease, but our understanding of advanced fibrosis in individuals with psoriasis is limited. OBJECTIVES: To describe the prevalence of and evaluate the clinical factors associated with advanced liver fibrosis in people with severe psoriasis. DESIGN, SETTING, AND PARTICIPANTS: The Co-morbidities in Severe Psoriasis study, a prospective observational cohort study in a large center serving London and Southeast England, was conducted from October 18, 2012, to April 2, 2015; 400 adults with severe psoriasis (Psoriasis Area Severity Index score, ≥10) were recruited from outpatient clinics. Statistical analysis was conducted from October 2, 2016, to March 3, 2017. MAIN OUTCOMES AND MEASURES: The primary outcome was a diagnosis of advanced liver fibrosis determined by transient elastography, a noninvasive criterion standard test. Clinical factors evaluated included psoriasis-specific and metabolic indices, alcohol use, and methotrexate exposure. RESULTS: Of 400 patients recruited (108 women and 289 men; mean [SD] age, 49.5 [13] years), 333 had a successful transient elastography scan and were included in final analysis. Forty-seven patients (14.1%; 95% CI, 10.4%-17.9%) had advanced liver fibrosis as diagnosed by transient elastography. The clinical factors that produced the best-fit model for advanced fibrosis were central obesity (waist circumference), insulin resistance, aspartate aminotransferase level, platelet count, psoriasis disease severity, and reduced alcohol use (R2 = 0.54). CONCLUSIONS AND RELEVANCE: Findings from this study suggest that advanced fibrosis is common in severe psoriasis. Abdominal obesity (by waist circumference) and insulin resistance were associated with the presence of advanced fibrosis. Longitudinal work to characterize the hepatic sequelae of central obesity, insulin resistance, and inflammation as well as the influence of systemic drugs (methotrexate and biologics) will inform future personalized therapeutic decision-making. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02174367.
引用
- Maybury CM, Porter HF, Kloczko E, et al. Prevalence of Advanced Liver Fibrosis in Patients With Severe Psoriasis. JAMA Dermatol. 2019. PMID: 31166567. doi:10.1001/jamadermatol.2019.0721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。